Documents

Rapidly scaling OSA therapy with robust clinical results, strong U.S. launch, and clear path to profit.

Q2 revenue grew 21% sequentially, with strong U.S. adoption, margin gains, and solid 2026 outlook.

Rapid U.S. adoption, strong financials, and innovation position Genio for OSA market leadership.

Rapid U.S. and international growth driven by innovative OSA therapy and strong clinical results.

Rapid U.S. commercialization and strong clinical results drive growth in sleep apnea neuromodulation.

Strong Q1 revenue growth and expanding U.S. market presence drive positive 2026 outlook.

Genio's unique sleep apnea therapy accelerates U.S. adoption with strong clinical and financial momentum.

Rapid U.S. launch and strong clinical results position Genio for significant market growth.

FDA approval and U.S. launch fueled 122% revenue growth and strong Q4 momentum.

Rapid U.S. launch, strong reimbursement, and pipeline progress signal robust growth ahead.

Q3 revenue up 56% as U.S. Genio launch accelerates, with strong outlook and new capital secured.

Focused U.S. expansion, strong reimbursement, and innovation drive growth amid new market opportunities.

U.S. launch of a differentiated OSA therapy follows robust clinical results and rapid market uptake.

US launch of a differentiated sleep apnea device targets growth, with strong financial planning.

FDA approval and strong U.S. launch drive 73.8% revenue growth, despite higher operating loss.

FDA approval for Genio expected Q2 2025; U.S. launch ready, cash runway into Q2 2026.

Genio's pivotal study success and U.S. launch readiness set the stage for transformative 2025 growth.

FDA approval expected Q1 2025 for a novel sleep apnea implant, with strong clinical results and U.S. launch plans.

DREAM study success and U.S. launch prep drive optimism, with FDA approval expected Q1 2025.